Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study

被引：0
|
作者：
Hubert G. Nüßlein
Rieke Alten
Mauro Galeazzi
Hanns-Martin Lorenz
Michael T. Nurmohamed
William G. Bensen
Gerd R. Burmester
Hans-Hartmut Peter
Karel Pavelka
Melanie Chartier
Coralie Poncet
Christiane Rauch
Manuela Le Bars
机构：
[1] University of Erlangen-Nuremberg,Institute of Rheumatology and Clinic of Rheumatology
[2] Schlosspark-Klinik University Medicine,undefined
[3] University of Siena,undefined
[4] University Hospital,undefined
[5] VU University Medical Center/Jan van Breeman Research Institute,undefined
[6] St Joseph’s Hospital/McMaster University,undefined
[7] Charité-Universitätsmedizin,undefined
[8] University Medical Center Freiburg,undefined
[9] Charles University,undefined
[10] Chiltern International,undefined
[11] Docs International,undefined
[12] Bristol‐Myers Squibb,undefined
[13] Bristol-Myers Squibb,undefined
来源：
BMC Musculoskeletal Disorders | / 16卷
关键词：
Abatacept; Biologic agents; Cyclic citrullinated peptide; Heart failure; Prognostic factors; Multivariate analysis; Retention; Rheumatoid arthritis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study
    Nuesslein, Hubert G.
    Alten, Rieke
    Galeazzi, Mauro
    Lorenz, Hanns-Martin
    Boumpas, Dimitrios
    Nurmohamed, Michael T.
    Bensen, William G.
    Burmester, Gerd R.
    Peter, Hans-Hartmut
    Rainer, Franz
    Pavelka, Karel
    Chartier, Melanie
    Poncet, Coralie
    Rauch, Christiane
    Le Bars, Manuela
    [J]. BMC MUSCULOSKELETAL DISORDERS, 2014, 15
  • [32] REAL WORD EXPERIENCE WITH TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: AN INTERIM ANALYSIS FROM A FRENCH PROSPECTIVE OBSERVATIONAL STUDY DeFacTo
    Gaujoux-Viala, C.
    Basch, A.
    Lassoued, S.
    Coury-Lucas, F.
    Kessouri, M.
    Mammar, N.
    Lequerre, T.
    Salliot, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 571 - 572
  • [33] Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study
    R. Westhovens
    S. E. Connolly
    J. Margaux
    M. Vanden Berghe
    M. Maertens
    M. Van den Berghe
    Y. Elbez
    M. Chartier
    F. Baeke
    S. Robert
    M. Malaise
    [J]. Rheumatology International, 2020, 40 : 1409 - 1421
  • [34] Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study
    Westhovens, R.
    Connolly, S. E.
    Margaux, J.
    Vanden Berghe, M.
    Maertens, M.
    Van den Berghe, M.
    Elbez, Y.
    Chartier, M.
    Baeke, F.
    Robert, S.
    Malaise, M.
    [J]. RHEUMATOLOGY INTERNATIONAL, 2020, 40 (09) : 1409 - 1421
  • [35] Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)
    Terpos, Evangelos
    Kastritis, Eftathios
    Hatjiharissi, Evdoxia
    Katodritou, Eirini
    Eleutherakis-Papaiakovou, Evangelos
    Verrou, Evgenia
    Gavriatopoulou, Maria
    Leonidakis, Alexandros
    Ntanasis-Stathopoulos, Ioannis
    Delimpasi, Sosana
    Kyrtsonis, Marie-Christine
    Papaioannou, Maria
    Symeonidis, Argiris
    Dimopoulos, Meletios A.
    [J]. BLOOD, 2019, 134
  • [36] UP TO 5-YEAR RETENTION OF ABATACEPT IN BELGIAN PATIENTS WITH MODERATE-TO-SEVERE RA: PROSPECTIVE DATA FROM THE REAL-WORLD ACTION STUDY
    Westhovens, R.
    Connolly, S. E.
    Margaux, J.
    Vanden Berghe, M.
    Maertens, M.
    Van den Berghe, M.
    Elbez, Y.
    Chartier, M.
    Baeke, F.
    Robert, S.
    Malaise, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1393 - 1393
  • [37] COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY IN PORTUGAL
    Paquete, A. T.
    Gouveia, M.
    Guerreiro, R.
    Anjo, J.
    Magalhaes, C.
    Borges, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S448 - S448
  • [38] Baseline Autoantibodies Preferentially Impact Abatacept Efficacy in Patients with RA who are Biologic Naive: 6-Month Results from a Real-World, International, Prospective Study
    Alten, Rieke
    Nuesslein, Hubert
    Galeazzi, Mauro
    Lorenz, Hannes
    Mariette, Xavier
    Cantagrel, Alain
    Chartier, Melanie
    Desachy, Guillaume
    Poncet, Coralie
    Rauch, Christiane
    Le Bars, Manuela
    Sladojevic, Kristina
    [J]. JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1210 - 1210
  • [39] Baseline Autoantibodies Preferentially Impact Abatacept Efficacy in Patients with RA Who Are Biologic Naive: 6-Month Results from a Real-World, International, Prospective Study
    Alten, R.
    Nuesslein, H. G.
    Galeazzi, M.
    Lorenz, H-M
    Mariette, X.
    Cantagrel, A.
    Chartier, M.
    Desachy, G.
    Poncet, C.
    Rauch, C.
    Le Bars, M.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [40] The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study
    Mariette, Xavier
    Alten, Rieke
    Nuesslein, Hubert G.
    Galeazzi, Mauro
    Lorenz, Hanns-Martin
    Cantagrel, Alain
    Chartier, Melanie
    Poncet, Coralie
    Rauch, Christiane
    Le Bars, Manuela
    [J]. JOINT BONE SPINE, 2017, 84 (05) : 571 - 576
12345